Gland Pharma gets nod for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)

07 Jan 2026 Evaluate

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc (Alcon). This product is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1698.95 -9.55 (-0.56%)
08-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1761.45
Dr. Reddys Lab 1207.50
Cipla 1460.60
Zydus Lifesciences 907.60
Lupin 2190.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×